Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915435 | 1.00 | TRPA1 (0.37) | TRPA1RIPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4735366 | 1.00 | TRPA1 (0.37) | TRPA1RIPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14564989 | 0.87 | TRPA1 (0.40) | TRPA1RIPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27032153 | 0.87 | TRPA1 (0.40) | TRPA1RIPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8391322 | 0.87 | TRPA1 (0.40) | TRPA1RIPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30425003 | 0.85 | TRPA1 (0.36) | TRPA1RIPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3991039 | 0.84 | LMNA (0.34) | TRPA1RIPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15295114 | 0.84 | TRPA1 (0.34) | TRPA1RIPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8175900 | 0.84 | TRPA1 (0.35) | TRPA1RIPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4455719 | 0.84 | TRPA1 (0.35) | TRPA1RIPK1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | TRPA1 123/4885RIPK1 2397/4885SLC6A2 426/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | TRPA1 260/4885RIPK1 2362/4885SLC6A2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.